Clinically, berzosertib (ATR inhibitor) has shown promise with topotecan in relapsed neuroendocrine cancers (110) and also improving outcomes with gemcitabine in platinum-resistant HGSOC (111) and Non-Small Cell Lung Cancer (NSCLC) with high TMB/LOH (112). This evidence concerns the gene ATR and neuroendocrine carcinoma.